Table 2.

Convergent validity of the Acro-TSQ, first and second study

Measure	Scale	Acromegaly symptoms	Treatment related GI side effects	Treatment satisfaction	Treatment administration bother	Treatment Convenience
Acro-TSQ scales, first study
TSQM	Effectiveness	0.29*	0.15	0.83**	0.31**	0.32**
	Side effects	0.15	0.36*	0.28*	0.44**	0.15
	Convenience	− 0.04	0.04	0.54**	0.60**	0.46**
	Overall satisfaction	0.21	0.31*	0.82**	0.27*	0.18
AcroQoL	Physical	0.58**	0.45**	0.41**	0.08	0.08
	Psychological	0.32*	0.46**	0.40**	0.02	0.001
	Physical appearance	0.30*	0.40**	0.45**	0.09	− 0.001
	Personal relationships	0.28*	0.44**	0.30**	− 0.06	0.001
	Global	0.46**	0.47**	0.43**	0.05	0.03

Measure	Scale	Symptom interference	Treatment convenience	Injection site interference	GI interference	Treatment satisfaction	Emotional reaction
Acro-TSQ scales, second study
AIS	Overall	− 0.54**	− 0.22*	− 0.39**	− 0.25*	− 0.44**	− 0.18
WPAI:SHP	Absenteeism	− 0.09	− 0.34*	− 0.32	− 0.36*	− 0.25	− 0.41*
	Presenteeism	− 0.36*	− 0.39*	− 0.34*	− 0.56**	− 0.28	− 0.51**
	Work Productivity Loss	− 0.41*	− 0.31	− 0.26	− 0.46**	− 0.23	− 0.42**
	Activity Impairment	− 0.56**	− 0.48**	− 0.40**	− 0.42**	− 0.54**	− 0.37**
EQ-5D-5L	Mobility	− 0.50**	− 0.40**	− 0.38**	− 0.33**	− 0.42**	− 0.30**
	Self-care	− 0.39**	− 0.40**	− 0.45**	− 0.47**	− 0.39**	− 0.36**
	Usual activities	− 0.58**	− 0.40**	− 0.42**	− 0.39**	− 0.45**	− 0.35**
	Pain/discomfort	− 0.56**	− 0.39**	− 0.37**	− 0.48**	− 0.48**	− 0.27*
	Anxiety/depression	− 0.35**	− 0.38**	− 0.14	− 0.28*	− 0.37**	− 0.37**
	EQ-VAS	0.49**	0.31**	0.36**	0.24*	0.37**	0.30**
IGF-1		− 0.27*	− 0.05	− 0.07	− 0.05	− 0.25*	− 0.07

Cell values are Pearson correlations at baseline of each study

*p < 0.05; **p < 0.01

Negative correlations represent situations where high scores on the Acro-TSQ scale correspond to lower scores on the collateral measure

Bold values indicate correlations > 0.30 in absolute value